Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a conference call and webcast scheduled for August 7, 2024, at 8:00 a.m. ET. The event will cover the company's second quarter 2024 results and provide a corporate update. Interested parties can access the call via phone or webcast, with U.S. callers dialing +1-800-343-4849 and international callers using +1-203-518-9848. The webcast will be available on the company's website, and a replay will be accessible approximately one hour after the call concludes.
Editas Medicine (Nasdaq: EDIT), un'azienda di editing genomico in fase clinica, ha annunciato una conferenza telefonica e un webcast programmati per il 7 agosto 2024, alle 8:00 ET. L'evento tratterà i risultati del secondo trimestre 2024 dell'azienda e fornirà un aggiornamento aziendale. Le parti interessate possono accedere alla chiamata tramite telefono o webcast, con i chiamanti dagli Stati Uniti che devono comporre il numero +1-800-343-4849 e i chiamanti internazionali che possono utilizzare +1-203-518-9848. Il webcast sarà disponibile sul sito web dell'azienda e una registrazione sarà accessibile circa un'ora dopo la conclusione della chiamata.
Editas Medicine (Nasdaq: EDIT), una empresa de edición genética en fase clínica, ha anunciado una conferencia telefónica y un webcast programados para el 7 de agosto de 2024 a las 8:00 a.m. ET. El evento cubrirá los resultados del segundo trimestre de 2024 de la compañía y proporcionará una actualización corporativa. Las partes interesadas pueden acceder a la llamada por teléfono o webcast, con los llamantes de EE. UU. marcando +1-800-343-4849 y los llamantes internacionales utilizando +1-203-518-9848. El webcast estará disponible en el sitio web de la compañía, y una repetición estará accesible aproximadamente una hora después de que finalice la llamada.
Editas Medicine (Nasdaq: EDIT), 임상 단계의 유전자 편집 회사가 2024년 8월 7일 오전 8:00 ET에 예정된 전화 회의 및 웹캐스트를 발표했습니다. 이 이벤트는 회사의 2024년 2분기 실적을 다루고 회사 업데이트를 제공합니다. 관련자는 전화나 웹캐스트로 전화를 통해 참가할 수 있으며, 미국 발신자는 +1-800-343-4849로 전화하고, 국제 발신자는 +1-203-518-9848을 이용해야 합니다. 웹캐스트는 회사 웹사이트에서 제공되며, 전화 회의가 종료된 후 약 한 시간 후에 재생이 가능합니다.
Editas Medicine (Nasdaq: EDIT), une entreprise de modification génétique en phase clinique, a annoncé une conférence téléphonique et un webcast prévus pour le 7 août 2024 à 8h00 ET. L'événement couvrira les résultats du deuxième trimestre 2024 de l'entreprise et fournira une mise à jour de l'entreprise. Les parties intéressées peuvent accéder à l'appel par téléphone ou par webcast, les appelants américains composant le +1-800-343-4849 et les appelants internationaux utilisant le +1-203-518-9848. Le webcast sera disponible sur le site web de l'entreprise et une rediffusion sera accessible environ une heure après la fin de l'appel.
Editas Medicine (Nasdaq: EDIT), ein Unternehmen für Genbearbeitung in der klinischen Phase, hat eine Telefonkonferenz und einen Webcast angekündigt, die für den 7. August 2024 um 8:00 Uhr ET geplant sind. Die Veranstaltung wird die Ergebnisse des zweiten Quartals 2024 des Unternehmens behandeln und ein Unternehmensupdate bereitstellen. Interessierte Parteien können über Telefon oder Webcast auf die Konferenz zugreifen, wobei Anrufer aus den USA die Nummer +1-800-343-4849 wählen und internationale Anrufer +1-203-518-9848 verwenden. Der Webcast wird auf der Website des Unternehmens verfügbar sein, und eine Wiederholung wird etwa eine Stunde nach dem Ende der Konferenz zugänglich sein.
- None.
- None.
CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET to discuss results for the second quarter 2024 and to provide a corporate update.
To access the conference call:
- U.S. callers should dial +1-800-343-4849 and international callers should dial +1-203-518-9848 approximately five minutes before the call begins.
- Participants should ask to be connected to the Editas Medicine Earnings Conference Call.
The conference call will also be webcast and can be accessed from the “Investors” section of the Editas Medicine website at https://www.editasmedicine.com. A replay will be available at the same site approximately one hour after the completion of the call.
About Editas Medicine
As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
FAQ
When is Editas Medicine (EDIT) hosting its Q2 2024 earnings call?
How can investors access Editas Medicine's (EDIT) Q2 2024 earnings call?
Will there be a replay available for Editas Medicine's (EDIT) Q2 2024 earnings call?
What topics will be covered in Editas Medicine's (EDIT) upcoming conference call?
